
LIST OF FIGURES

Figure 3.1 Primary sequence and domain architecture of STIM1 and STIM2.....	15
Figure 3.2 Predicted domains within human STIM1.....	17
Figure 3.3 Model for STIM1-Orai coupling.....	20
Figure 3.4 A model of SOCE microdomain organization.	22
Figure 4.1 Piper betle Leaf.....	28
Figure 4.2 Rubia cordifolia Root	31
Figure 6.1 Powder microscopy of <i>Piper betle</i> Lin.....	98
Figure 6.2 Powder microscopy of <i>Rubia Cordifolia</i> Lin.	99
Figure 6.3 Calibration curve of Gallic acid.	102
Figure 6.4 Calibration curve of Quarcetin.	103
Figure 6.5 Chromatogram of Eugenol.	104
Figure 6.6 Calibration curve of Eugenol by GC-FID.	105
Figure 6.7 Chromatogram of PBEA.	105
Figure 6.8 Chromatogram of RCHA.	106
Figure 6.9 Primary screening of Eugenol and its identification in PBEA and RCHA.	107
.....	107
Figure 6.10 HPTLC chromatogram of Eugenol in PBEA under UV light.....	107
Figure 6.11 HPTLC Chromatogram of Eugenol.....	108
Figure 6.12 Calibration curve of Eugenol by HPTLC.....	109
Figure 6.13 HPTLC Chromatogram of PBEA.....	109
Figure 6.14 DPPH assay of Plant extracts and standards.	110
Figure 6.15 Superoxide anion radical scavenging assay of plant extracts.....	111
Figure 6.16 Hydroxyl radical scavenging activity of plant extracts.	112
Figure 6.17 Hydrogen peroxide scavenging activity of plant extracts.	113
Figure 6.18 Reducing power assay of plant extracts.	113
Figure 6.19 IR spectra of 2-APB.	114
Figure 6.20 Wavelength detection of 2-APB by UV	115
Figure 6.21 Chromatogram of 2-APB by HPLC.	116
Figure 6.22 Calibration curve of 2-APB.....	117
Figure 6.23 Calibration curve of 2-APB.....	119

Figure 6.24 Cell cytoprotectivity assay of PBEA.	124
Figure 6.25 Cell cytoprotectivity assay of RCHA.	124
Figure 6.26 Cell cytoprotectivity assay of 2-APB.	125
Figure 6.27 Cell cytoprotectivity assay of Eugenol.	126
Figure 6.28 DCFH-DA assay of drugs.	127
Figure 6.29 Apoptosis assay of drugs.	129
Figure 6.30 Vascular reactivity assay of extracts and standards.	130
Figure 6.31 Effect of drugs on systolic blood pressure in Ag-II induced acute hypertension.	131
Figure 6.32 Effect of drugs on diastolic blood pressure in Ag-II induced acute hypertension.	132
Figure 6.33 Effect of drugs on calcium level at different time point in Ag-II induced.	133
Figure 6.34 Effect of drugs on sodium level at 0.5 min in Ag-II induced acute hypertension.	134
Figure 6.35 Effect of drugs on magnesium level at 0.5 min in Ag-II induced	135
Figure 6.36 Effect of drugs on heart and kidney malondialdehyde level in Ag-II induced	136
Figure 6.37 Effect of drugs on heart and kidney SOD level in Ag-II induced	137
Figure 6.38 Effect of drugs on heart and kidney Catalase level in Ag-II induced	138
Figure 6.39 Effect of drugs on heart and kidney GSH level in Ag-II induced	139
Figure 6.40 Effect of drugs on aorta STIM1 and Orai1 in Ag-II induced acute hypertension.	140
Figure 6.41 Effect of drugs on heart STIM1 and Orai1 in Ag-II induced acute hypertension.	142
Figure 6.42 Effect of drugs on kidney STIM1 and Orai1 in Ag-II induced acute hypertension.	144
Figure 6.43 Effect of PBEA and RCHA on CK-MB in ISO induced global ischemia.	145
Figure 6.44 Effect of PBEA and RCHA on LDH in ISO induced global ischemia.	146
Figure 6.45 Effect of PBEA and RCHA on MDA in ISO induced global ischemia.	147

Figure 6.46 Effect of PBEA and RCHA on GSH in ISO induced global ischemia.	148
Figure 6.47 Effect of 2-APB on calcium level at different time point in ISO induced global ischemia.....	149
Figure 6.48 Effect of drugs on blood pressure in ISO induced global ischemia.	150
Figure 6.49 Electro cardiographic pattern of different drug on ISO induced global ischemia	152
Figure 6.50 Effect of drugs on dp/dt in ISO induced global ischemia.	155
Figure 6.51 Effect of drugs on heart weight/ body weight ratio in ISO induced global ischemia.	156
Figure 6.52 Effect of drugs on CK-MB in ISO induced global ischemia.....	156
Figure 6.53 Effect of drugs on LDH in ISO induced global ischemia.	157
Figure 6.54 Effect of drugs on serum calcium level in ISO induced global ischemia.	158
Figure 6.55 Effect of drugs on heart calcium level in ISO induced global ischemia.	158
Figure 6.56 Effect of drugs on potassium level in ISO induced global ischemia.....	159
Figure 6.57 Effect of drugs on sodium level in ISO induced global ischemia.	160
Figure 6.58 Effect of drugs on TNF- α level in ISO induced global ischemia.	160
Figure 6.59 Effect of drugs on IL-6 level in ISO induced global ischemia.....	161
Figure 6.60 Effect of drugs on Na ⁺ /K ⁺ ATPase activity in ISO induced global ischemia.	164
Figure 6.61 Effect of drugs on Ca ⁺⁺ ATPase activity in ISO induced global ischemia.	165
Figure 6.62 Effect of drugs on Mg ⁺⁺ ATPase activity in ISO induced global ischemia.	165
Figure 6.63 Effect of drugs on nitrite level in ISO induced global ischemia.	166
Figure 6.64 Effect of drugs on MPO level in ISO induced global ischemia.	167
Figure 6.65 Effect of drugs on infarct size in ISO induced global ischemia.	168
Figure 6.66 Effect of drugs on histopathology on heart tissue in ISO induced global ischemia. Magnification 10X and 20X with 200 μ m Scale.	170
Figure 6.67 Effect of drugs on STIM1 and Orail expression in ISO induced	

global ischemia.	172
Figure 6.68 Effect of drugs on CK-MB level in LAD induced cardiotoxicity.	173
Figure 6.69 Effect of drugs on STIM1 and Orai1 expression in LAD induced reperfusion injury.	174
Figure 6.70 Cell Cytotoxicity of PBEA.	175
Figure 6.71 Cell Cytotoxicity of RCHA.	175
Figure 6.72 Cell Cytotoxicity of 2-APB.	176
Figure 6.73 Effect of drugs on LDH level in DOXO induced cardiotoxicity.	177
Figure 6.74 Effect of drugs on STIM1 and Orai1 expression in DOXO induced cardiotoxicity.	178
Figure 6.75 Histopathological analysis of female organs treated with PBEA in the sub-acute toxicity.	189
Figure 6.76 Histopathological analysis of male organs treated with PBEA in the sub-acute toxicity.	190